{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-016162","form_type":"8-K/A","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.469782+00:00","generated_at":"2026-06-02T02:24:36.694000+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Moleculin reports Q1 2024 results; Annamycin shows 62% CRc in 1st/2nd line AML","bullets":["R&D expense $4.3M, G&A $2.4M; cash $16.8M sufficient into Q4 2024.","MB-106 interim data: CRc 62% (54% CR) in 1st/2nd line AML (N=13).","All lines CRc 45% across 20 subjects; median durability 4.9 months and climbing.","Milestones: complete MB-106 H1 2024; EOP2 meeting H1 2024; pivotal trial H1 2025.","Received EMA Orphan Drug Designation for Annamycin in AML; U.S. patents issued."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-016162","json":"https://secwatch.observer/filing/0001437749-24-016162.json","markdown":"https://secwatch.observer/filing/0001437749-24-016162.md","text":"https://secwatch.observer/filing/0001437749-24-016162.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774924016162/0001437749-24-016162-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774924016162/mbrx20240513_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:24:36.694000+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7958d46b87e0c8ac3d9e729f4ba027b8b570e321","claim":"Moleculin Biotech, Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 13, 2024, Moleculin Biotech, Inc. issued an updated press release announcing its financial results for the quarter ended March 31, 2024 and recent operational highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774924016162/0001437749-24-016162-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}